Interleukin-28B Polymorphisms Are Associated With Histological Recurrence and Treatment Response Following Liver Transplantation in Patients With Hepatitis C Virus Infection
Michael R Charlton, Alexander Thompson, Bart J Veldt, Kym Watt, Hans Tillmann, John J Poterucha, Julie K Heimbach, David Goldstein, John McHutchison
HEPATOLOGY | WILEY | Published : 2011
UNLABELLED: Polymorphism in the interleukin-28B (IL28B) gene region, encoding interferon (IFN)-λ3, is strongly predictive of response to antiviral treatment in the nontransplant setting. We sought to determine the prevalence and impact on clinical outcomes of donor and recipient IL28B genotypes among liver transplant recipients. The cohort study included 189 consecutive patients infected with hepatitis C virus (HCV) who underwent liver transplantation between January 1, 1995, and January 1, 2005, at the Mayo Clinic, Rochester, MN. Genotyping of the polymorphism rs12979860 was performed on DNA collected from all donors and recipients in the cohort. Sixty-five patients received IFN-based antiv..View full abstract
Awarded by U.S. Public Health Service
Awarded by NATIONAL CENTER FOR RESEARCH RESOURCES
This work has been supported by U.S. Public Health Service grant GCRC RR00585.Potential conflict of interest: One of the authors, J.M., has a significant financial interest in IL28B genotyping. To manage this potential conflict of interest, J.M. (and the entire Duke team) was blinded to all posttransplant outcomes at the time of genotyping. Only after all genoving was performed and the results disclosed to Mayo investigators were outcomes metrics disclosed to the Duke collaborators, including J.M. No one at Mayo has any financial interest in IL28B testing. Dr. McHutchison is employed by and receives grants from Merck/Schering-Plough. Dr. McHutchison receives grants from Roche and holds intellectual property rights IL28B patent with Labcorp. Dr. Goldstein receives grants from GSK Research and holds intellectual property rights IL28B patent with Labcorp.